Winhe Pharma Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2008

Location

Yuxi Yunnan China

Primary Industry

Pharmaceuticals

About

Established in 2008 and based in Yuxi, China, Winhe Pharma is a pharmaceutical company whose business integrates product research and development, drug production, herb cultivation and sales. The company has a GMP-certified production plant covering an area of more than 100 acres, 6500 acres of original ecological medicinal herbs plantation base, and the R&D center has been recognized as Yunnan Provincial Enterprise Technology Center. In April 2016, it closed a round of strategic investment. The company is mainly engaged in the research and development, production and sales of natural plant medicines with Panax notoginseng as the main raw material, as well as the plantation business of Panax notoginseng and other Chinese herbal medicines. The products are mainly cardiovascular and cerebrovascular drugs, supplemented by drugs for bruises and injuries, dispelling wind and removing dampness, and tonifying and nourishing blood, mainly including the Haematoxylin series, which consists of Haematoxylin Tablets, Haematoxylin Capsules and other 56 categories.

Current Investors

GTJA Innovation Investment, CITIC Kingview Capital Management, New Margin Capital

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Pharmaceutical Research & Development

Website

www.winhey.com.cn

Company Stage

Series C

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.